Medicaid’s expenditures for newer pharmacotherapies for adults with disabilities

Issue Date
2007Author
Shireman, Theresa I.
Hall, Jean P.
Rigler, Sally K.
Moore, Janice M.
Publisher
Health Care Financing Review
Type
Article
Article Version
Scholarly/refereed, publisher version
Metadata
Show full item recordAbstract
Medicaid's drug expenditures have grown at double-digit inflation rates since 2000. These prescription drug costs are important contributors to increasing health care costs for disabled persons. In spite of this knowledge, little has been reported about specific patterns of medication use among disabled enrollees. We analyzed Kansas Medicaid data to describe trend in medication use patterns across 3 years among disabled beneficiaries. The marked shifts toward newer medications and disproportionate contributions of newer, more expensive medications to overall prescription costs for antipsychotics, antidepressants, anticonvulsants, antiulcer medications, anti-inflammatory agents, and opioids have implications for both policy and practice.
Collections
Citation
Shireman, T.I., Hall, Jean, P., Rigler, S.K., & Moore, J.M. (2007). Medicaid’s expenditures for newer pharmacotherapies for adults with disabilities. Health Care Financing Review, 28(4), 31-41.
Items in KU ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
We want to hear from you! Please share your stories about how Open Access to this item benefits YOU.